Arbutus Biopharma Corporation ABUS
Nov 4, 2026, 2:58 PM EST
- YTD
- -16.12%
- 1 year
- -10.34%
- Market cap
- 618.47M
- Revenue (ttm)
- 181.72M
- Profit margin
- 84.23%
- EPS (ttm)
- 0.79
- Shares out
- 198.11M
- P/E ratio
- 5.11
- Forward P/E
- -30.67
- YTD return
- -16.12%
- 1-year return
- -10.34%
- Volume
- 1.31M
- Avg volume
- 4.95M
- Open
- 3.98
- Previous close
- 3.88
- Day's range
- 3.87 – 4.07
- 52-week range
- 3.50 – 5.45
- Beta
- 0.62
- Price target
- 5.46 (+35.3%)
- Earnings date
- Nov 16, 2026
5D -0.33 (-7.53%)
Key statistics
- Enterprise value
- 910.13M
- PEG ratio
- 0.00
- Price / sales
- 5.53
- Price / book
- 3.87
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -90.60%
- Free cash flow
- -80.24M
- Total cash
- 92.63M
- Total debt
- 3.63M
- Return on equity
- 89.58%
- Short % of float
- 14.19%
- 50-day average
- 4.79
- 200-day average
- 4.52
Analyst view
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 16, 2026
Expected Nov 16, 2026. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 16, 2026 | Sep 30, 2026 | -0.0232 | — | — | — |
| Aug 12, 2026 | Jun 30, 2026 | -0.02 | -0.03 | -0.01 | -50.00% |
| May 13, 2026 | Mar 31, 2026 | -0.03 | 0.87 | +0.90 | +3,000.00% |
| Mar 23, 2026 | Dec 31, 2025 | -0.03505 | -0.01 | +0.03 | +71.47% |
| Nov 13, 2025 | Sep 30, 2025 | -0.056 | -0.04 | +0.02 | +28.57% |
| Aug 6, 2025 | Jun 30, 2025 | -0.02 | 0.01 | +0.03 | +150.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2025 | Chardan Capital | main | Buy | Buy |
| Aug 11, 2025 | Chardan Capital | main | Buy | Buy |
| Mar 28, 2025 | Chardan Capital | main | Buy | Buy |
| Jan 21, 2025 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 20, 2024 | Chardan Capital | main | Buy | Buy |
| Nov 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Arbutus Biopharma Corporation
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- arbutusbio.com
News
FDA Lifts Three-Year Freeze On Arbutus Biopharma's Hepatitis B Study 
Arbutus Biopharma Says FDA Lifts Clinical Hold On AB-101 IND, Company May Now Engage In Additional Clinical Development For AB-101 In US 
Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor 
Arbutus Biopharma: $230M Buyback And Moderna Cash De-Risk The Path To A Potential HBV Cure 
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Up 5.3% – Here’s What Happened 
Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer 
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer 
10 Health Care Stocks With Whale Alerts In Today’s Session 
Connor Clark & Lunn Investment Management Ltd. Buys Shares of 130,023 Arbutus Biopharma Corporation $ABUS 
Bank of America Corp DE Has $7.58 Million Stock Position in Arbutus Biopharma Corporation $ABUS
Your note
Sign in to keep a note on ABUS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDROSKI LINDSAY J.D. | Chief Executive Officer | Stock Award(Grant) | Feb 1, 2026 | 28,000 |
| HASTINGS DAVID C | Chief Financial Officer | Stock Award(Grant) | Feb 13, 2025 | 249,824 |
| NAFTZGER J CHRISTOPHER | General Counsel | Stock Award(Grant) | Feb 13, 2025 | 140,544 |
| NGUYEN TUAN | Chief Financial Officer | Stock Award(Grant) | Feb 1, 2026 | 73,500 |
| SIMS KAREN | Officer | Stock Award(Grant) | Feb 13, 2025 | 155,494 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Two Seas Capital Lp | 9.64% | 19,095,583 | 96.81M | Jun 29, 2026 |
| Morgan Stanley | 8.93% | 17,698,305 | 89.73M | Jun 29, 2026 |
| Whitefort Capital Management, LP | 7.97% | 15,794,261 | 80.08M | Jun 29, 2026 |
| Blackrock Inc. | 6.95% | 13,766,071 | 69.79M | Jun 29, 2026 |
| State Street Corporation | 3.97% | 7,869,179 | 39.90M | Jun 29, 2026 |
| Rubric Capital Management LP | 3.80% | 7,532,937 | 38.19M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.54% | 5,034,547 | 25.53M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.03% | 4,020,969 | 20.39M | Jul 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.82% | 3,610,292 | 18.30M | Jul 30, 2026 |
| Morgan Stanley Insight Fund | 1.38% | 2,728,775 | 13.83M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.91% | 1,795,131 | 9.10M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.88% | 1,743,856 | 8.84M | Jun 29, 2026 |